Beijing KEY-BIO Biotech Co., LTD. (referred to as "KEY-BIO") was founded in 2007 and is a high-tech enterprise focusing on the core technology of detection reagents and the research and development of intelligent detection equipment. The company has a research and development base in Fengtai, Beijing and a production demonstration base in Daxing, with a total construction area of 6,400 square meters. Since being recognized as a national high-tech enterprise in 2016, It has successively passed the ISO9001 Quality Management System Certification, ISO14001 Environmental Management System Certification, ISO45001 Occupational Health and Safety Management System Certification, GB/T29490-2023 Intellectual Property Management System Certification, and ISO56005 Innovation and Intellectual Property Management Capability Certification. It is a "dual-independent enterprise" in Beijing.

The enterprise has strong honors and qualifications: In 2022, it was successively recognized as a Beijing Specialized, Refined, Unique and Innovative "Little Giant" enterprise and a national specialized, Refined, Unique and innovative "Little Giant" enterprise. It was also awarded as one of the top 100 small and medium-sized private enterprises in Beijing in 2022. In 2023 and 2024, it was consecutively selected as one of the top 100 specialized, refined, unique and innovative enterprises in Beijing. It was selected as one of the top 100 high-growth enterprises in Zhongguancun for three consecutive years from 2021 to 2023. From 2022 to 2025, it was consecutively recognized as a leading enterprise in innovation and credit in Beijing. In 2023, it won the "16th National Commercial Quality Award" and the "Third Prize" of the National Service Industry Science and Technology Innovation Award. In 2025, it won the "Second Prize" of the Private Science and Technology Development Contribution Award, the 2024 Science and Technology Innovation Award, and the "Second Prize" of the 19th Beijing Invention and Innovation Competition. In 2024, it was rated as a "5A" in the evaluation of the innovation capacity of high-tech enterprises, and was selected as a support unit for the layout of invention patents by technology-based small and medium-sized enterprises and a Beijing intellectual property advantage unit. It has been rated as an "A-level Tax Credit Enterprise" for more than 11 consecutive years.

The company has a solid accumulation of scientific research achievements: Currently, it holds 37 authorized invention patents, 1 utility model patent, and 1 design patent, has obtained 19 registered trademarks, and has drafted 3 group standards that have been released.

The core business achievements of the enterprise

Zhongkai Biology has been deeply engaged in the research and development, production and industrial application of core raw materials for in vitro diagnostics and full-scenario detection products, consolidating the core foundation of the industry. Its business layout covers three core tracks: core raw materials for scientific research, home rapid detection, and smart wearable health monitoring. It has built a health detection industrial system that is technologically leading, has a complete range of products, and features diverse scenarios throughout the entire chain. The comprehensive market competitiveness and industry influence have continued to rise.

In the core raw material base business of in vitro diagnostics, the company mainly operates various high-quality key raw materials for disease detection, including antigens, antibodies and markers. The product categories comprehensively cover core clinical areas with essential needs such as infectious disease screening, gonadal hormone detection, precise judgment of thyroid hormones, tumor marker screening, cytokine detection and assessment of heart and kidney functions. The core raw material products have extremely strong adaptability and high technical maturity, and can be fully compatible with mainstream in vitro diagnostic detection platforms such as ELISA enzyme-linked immunosorbent assay, plate chemiluminescence, magnetic microparticle-ALP chemiluminescence, magnetic microparticle-acridinium esterification chemiluminescence, immunochromatography, microfluidic detection, and biochemical turbidimetry. It can meet the core demands of large-scale production and precise testing for medical institutions at all levels, testing institutions and biopharmaceutical enterprises. The quality of raw materials has been verified through market practice for a long time.

In the field of home rapid testing and instant testing for the public, the company focuses on the essential needs of home health self-testing and rapid screening at the grassroots level. It prioritizes the layout of a lightweight, convenient and precise rapid testing product matrix, and builds a diversified and mature testing technology platform. Relying on the independent dry biochemical detection platform, only a small amount of blood drawn from the fingertip is needed to quickly complete the one-stop rapid detection of core organ and lipid health indicators such as four liver function items, three kidney function items, and four lipid items. It is equipped with self-developed immunofluorescence detection equipment, which can accurately and quickly determine the content of VD3 vitamin in the human body, meeting the nutritional and health monitoring needs of the general public. The colloidal gold series of rapid detection products are rich in variety and can efficiently complete the rapid screening of common and high-incidence infectious diseases such as Helicobacter pylori infection, influenza A and B, and norovirus. They are easy to operate and provide results quickly, suitable for various application scenarios such as home self-testing, primary clinics, and campus screening, benefiting the health management of all citizens.

In the future innovative business of smart wearable health monitoring, the company has proactively laid out the new track of intelligent monitoring for the big health industry, continuously increased investment in the research and development and market promotion of wearable medical detection products, and promoted the upgrade of health detection from passive screening to active real-time monitoring. The core is to create an intelligent health monitoring ring that can accurately and in real time monitor basic vital signs such as heart rate and blood oxygen saturation throughout the day. Equipped with dynamic electrocardiogram detection devices, it can continuously and dynamically capture heart health data, accurately assess the status of heart function, and connect the entire process of daily health monitoring, chronic disease prevention, and heart health early warning, building a new ecosystem of intelligent, regular, and professional health monitoring at home.

The company has always adhered to the core driving force of technological innovation. The key performance evaluation indicators of all its core products have reached and exceeded the world-class industry standards. Relying on its excellent product quality, complete industrial layout, and cutting-edge technological research and development capabilities, the brand reputation has continuously accumulated. The market share of its core products has steadily increased year by year, firmly remaining in the high-quality development echelon of the industry. In the future, we will continue to focus on the field of health detection and continuously empower the high-quality development of precision medicine and the cause of national health.